Allele specific gain-of-function activity of p53 mutants in lung cancer cells

Biochemical and Biophysical Research Communications

Volumn 428, Issue 1, 2012, Pages 6-10

  Vaughan, Catherine A ^a   Frum, Rebecca ^c   Pearsall, Isabella ^b   Singh, Shilpa ^a   Windle, Brad ^a,b   Yeudall, Andrew ^a,b   Deb, Swati P ^a,b   Deb, Sumitra ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allele; In vivo; Mutant; P53; Specificity

Indexed keywords

PROTEIN P53;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE TARGETING; GROWTH RATE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; WILD TYPE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, P53; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; SUPPRESSION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

MUS MUSCULUS;

EID: 84868359914     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.029     Document Type: Article

References (30)

1. Chang Y.L., Wu C.T., Shih J.Y., Lee Y.C. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann. Surg. Oncol. 2011, 18:543-550.
2. Harris C.C. p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996, 17:1187-1198.
3. Bronte G., Rizzo S., La Paglia L., Adamo V., Siragusa S., Ficorella C., Santini D., Bazan V., Colucci G., Gebbia N., Russo A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 2010, 36(Suppl. 3):S21-29.
4. Vandin F., Upfal E., Raphael B.J. De novo discovery of mutated driver pathways in cancer. Genome Res. 2012, 22:375-385.
5. Campling B.G., El-Deiry W.S. Clinical implication of p53 mutation in lung cancer. Mol. Biotechnol. 2003, 24:141-156.
6. Mogi A., Kuwano H. TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol. 2011, 583929.
7. Nakajima T., Yasufuku K., Nakagawara A., Kimura H., Yoshino I. Multi-gene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by EBUS-TBNA. Chest. 2011, 140:1319-1324.
8. Lai S.L., Perng R.P., Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J. Biomed. Sci. 2000, 7:64-70.
9. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485.
10. Li R., Sutphin P.D., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998, 16:3269-3277.
11. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
12. Lin J., Teresky A.K., Levine A.J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 1995, 10:2387-2390.
13. Lanyi A., Deb D., Seymour R.C., Ludes-Meyers J.H., Subler M.A., Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene 1998, 16:3169-3176.
14. Taylor W.R., Egan S.E., Mowat M., Greenberg A.H., Wright J.A. Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene 1992, 7:1383-1390.
15. Scian M.J., Stagliano K.E., Anderson M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., Deb S. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol. Cell Biol. 2005, 25:10097-10110.
16. Murphy K.L., Dennis A.P., Rosen J.M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 2000, 14:2291-2302.
17. Yeudall W.A., Vaughan C.A., Miyazaki H., Ramamoorthy M., Choi M.Y., Chapman C.G., Wang H., Black E., Bulysheva A.A., Deb S.P., Windle B., Deb S. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012, 33:442-451.
18. Vaughan C.A., Singh S., Windle B., Sankala H.M., Graves P.R., Andrew Yeudall W., Deb S.P., Deb S. P53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity. Arch. Biochem. Biophys. 2012, 518:79-88.
19. Scian M.J., Stagliano K.E., Ellis M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., Deb S. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 2004, 64:7447-7454.
20. Cadwell C., Zambetti G.P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001, 277:15-30.
21. Sigal A., Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000, 60:6788-6793.
22. Singer S., Ehemann V., Brauckhoff A., Keith M., Vreden S., Schirmacher P., Breuhahn K. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007, 46:759-768.
23. Strano S., Dell'Orso S., Di Agostino S., Fontemaggi G., Sacchi A., Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 2007, 26:2212-2219.
24. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., Rotter V., Blandino G., Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 2007, 67:2396-2401.
25. Yoshikawa K., Hamada J., Tada M., Kameyama T., Nakagawa K., Suzuki Y., Ikawa M., Hassan N.M., Kitagawa Y., Moriuchi T. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed. Res. 2010, 31:401-411.
26. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.C., Lambrechts D., Suh Y.A., Rousseau F., Schymkowitz J. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
27. Vaughan C.A., Singh S., Windle B., Sankala H.M., Graves P.R., Andrew Yeudall W., Deb S.P., Deb S. P53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity. Arch. Biochem. Biophys. 2012, 518:79-88.
28. Vaughan C.A., Singh S., Windle B., Sankala H.M., Graves P.R., Andrew Yeudall W., Deb S.P., Deb S. P53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity. Arch. Biochem. Biophys. 2011, 518:79-88.
29. Barton C.E., Johnson K.N., Mays D.M., Boehnke K., Shyr Y., Boukamp P., Pietenpol J.A. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death Dis. 2010, 1:74.
30. Levrero M., De Laurenzi V., Costanzo A., Gong J., Wang J.Y., Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 2000, 113(Pt. 10):1661-1670.